Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved cyanocobalamin nasal spray, 500 mcg/spray (one spray per device),
Cyanocobalamin nasal spray, 500 mcg/spray (one spray per device) is a generic equivalent of Nascobal nasal spray, 500 mcg/spray of Par Pharmaceutical, Inc.
It is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anaemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement; Treatment of adult patients with dietary, drug-induced, or malabsorption related vitamin B12 deficiency not due to pernicious anaemia; Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements more than normal.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
